ContinuingEducationCE
Page 14 / New Jersey AIDSLine, Summer 2015
ConclusionIn this article, we have summarized vaccination recommenda-tions for HIV-infected infants, children, adults, and adults >65 years of age. Immunization with attenuated and live vaccines are an integral part of the health care maintenance of all HIV-infected persons and have led to significant reductions in in-fectious disease morbidity and mortality. However, coverage has not reached the 90% goals as outlined in the Center for Disease Control’s Healthy People 2020 initiative.91 This age-specific review of vaccines should help providers become in-creasingly comfortable with recommended vaccinations among HIV-infected persons of all ages.
Summary Tables
Vaccines for HIV-infected infants and children ages 0-6 yearsHAV 2 dose series in second year of life
HBVa,b 3 dose series in first year of life
Influenza Inactivated Vaccinec 1 dose annually
Pneumococcal Conjugate Vaccine (PCV13)d
4 dose series in infants
Pneumococcal Polysaccharide Vaccine (PPSV23)
1 dose age ≥2 years, 8 weeks after PCV13
DTaP 5 dose series
MMRe 2 dose series in second year of life
VZVe 2 dose series in second year of life
NOTES. a Can use Engerix-B or RecombivaxHB, vaccines are interchangeable. b If non-immune 1 month after completion of series, repeat 3 dose
primary series once. c Children 6 months to 8 years of age who were previously not immunized
against influenza, should receive 2 doses at least 4 weeks apart. d If 14-71 months old and completed series with PCV 7, give one
supplemental dose of PCV 13. e If meets CD4 % and/or cell count as outlined in text.
Vaccines for HIV-infected children and adolescents ages 7-18 yearsHAV 2 dose series if not vaccinated
HBVa,b 3 dose series if not vaccinated
HPV 3 dose series
Influenza Inactivated Vaccine 1 dose annually
Pneumococcal Conjugate Vaccine (PCV13)
1dose
Pneumococcal Polysaccharide Vaccine (PPSV23)
2 doses max, 5 years apart
Tdap 1 dose TdaP age 11-12
MMRc 2 doses if no evidence of immunity
VZVc 2 doses if no evidence of immunity
NOTES. a Can use Engerix-B or RecombivaxHB, vaccines are interchangeable. b If non-immune repeat 3 dose primary series once. c If meets CD4 % and/or cell count as outlined in text.
Vaccines for HIV-infected adult ages 19-64 yearsHepatitis Aa
Hepatitis Bb
Td every 10 years
Tdap once in adulthood as substitute for Td
Inactivated Influenza annually
Pneumococcal Polysaccharide Vaccine (PPSV23)
1-2 doses, 5 years apart
Pneumococcal Conjugate Vaccine (PCV13)
once in adulthood
MMRc
Human Papillomavirusd
NOTES. a 2 dose series if no evidence of immunity. b 3 dose series if no evidence of immunity. c If meets CD4 % and cell count as outlined in text. d Recommended through age 26.
Vaccines for HIV-infected Adults Age >65 yearsHepatitis Aa
Hepatitis Bb
Td every 10 years
Tdap once if not done 19-64 years
Inactivated Influenza annually
Pneumococcal Polysaccharide Vaccine (PPSV23)
once
Pneumococcal Conjugate Vaccine (PCV13)
once if not done 19-64 years
MMRc
NOTES. a 2 dose series if no evidence of immunity. b 3 dose series if no evidence of immunity. c If meets CD4 % and cell count as outlined in text.